Wadhwa Jyoti, Asthana Abhay, Gupta Sumeet, Shilkari Asthana Gyati, Singh Ranjit
MM College of Pharmacy, MM University, Mullana, Ambala 133207, India.
Government College of Pharmacy, Rohru, Shimla 171207, India.
ScientificWorldJournal. 2014;2014:516069. doi: 10.1155/2014/516069. Epub 2014 Nov 24.
The purpose of the present study was to formulate polymeric self-emulsifying curcumin nanocapsules with high encapsulation efficiency, good emulsification ability, and optimal globule size for localized targeting in the colon. Formulations were prepared using modified quasiemulsion solvent diffusion method. Concentration of formulation variables, namely, X1 (oil), X2 (polymeric emulsifier), and X3 (adsorbent), was optimized by design of experiments using Box-Behnken design, for its impact on mean globule size (Y1) and encapsulation efficiency (Y2) of the formulation. Polymeric nanocapsules with an average diameter of 100-180 nm and an encapsulation efficiency of 64.85±0.12% were obtained. In vitro studies revealed that formulations released the drug after 5 h lag time corresponding to the time to reach the colonic region. Pronounced localized action was inferred from the plasma concentration profile (C max 200 ng/mL) that depicts limited systemic absorption. Roentgenography study confirms the localized presence of carrier (0-2 h in upper GIT; 2-4 h in small intestine; and 4-24 h in the lower intestine). Optimized formulation showed significantly higher cytotoxicity (IC50 value 20.32 μM) in HT 29 colonic cancer cell line. The present study demonstrates systematic development of polymeric self-emulsifying nanocapsule formulation of curcumin for localized targeting in colon.
本研究的目的是制备具有高包封率、良好乳化能力和最佳球粒尺寸的聚合物自乳化姜黄素纳米胶囊,用于结肠局部靶向。采用改良的准乳液溶剂扩散法制备制剂。通过Box-Behnken设计的实验设计,优化制剂变量X1(油)、X2(聚合物乳化剂)和X3(吸附剂)的浓度,以研究其对制剂平均球粒尺寸(Y1)和包封率(Y2)的影响。获得了平均直径为100-180nm、包封率为64.85±0.12%的聚合物纳米胶囊。体外研究表明,制剂在5小时的滞后时间后释放药物,这与到达结肠区域的时间相对应。从描述有限全身吸收的血浆浓度曲线(Cmax 200ng/mL)推断出明显的局部作用。X射线造影研究证实了载体的局部存在(在上消化道中为0-2小时;在小肠中为2-4小时;在大肠中为4-24小时)。优化后的制剂在HT 29结肠癌细胞系中显示出显著更高的细胞毒性(IC50值为20.32μM)。本研究展示了用于结肠局部靶向的姜黄素聚合物自乳化纳米胶囊制剂的系统开发。